Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
RegulatoryapprovedItvismaPositive
AI Analysis
Summary
Novartis received European Commission approval for Itvisma, a gene replacement therapy for spinal muscular atrophy, marking the first such treatment for a broad SMA population.
Outcome Details
European Commission approval for gene replacement therapy
Importance:8/10
Sentiment:
0.90
gene therapySMAEuropean Commissionregulatory approvalfirst-in-class
Related Companies
Read the original article
Published by PharmaTimes on July 2, 2026 1:32 PM